Scholarlink

<p>Genetic profiling of a new HPV-negative cervical cancer model identified pathogenic variants in genes implicated in oncogenic signaling, cell cycle regulation, and DNA damage repair pathways, including homologous recombination, non-homologous end-joining, and mismatch repair. Deficiencies in <i>BRCA</i>2, RAD51 and MLH1 were among these actionable targets. The newly described cervical cancer model revealed sensitivity towards the PARP inhibitor olaparib, which was further augmented upon combination with platinum-based chemotherapeutics. In contrast, <i>BRCA1/2</i>-proficient cervical cancer cells exhibited greater resistance to these strategies. This study highlights the potential of in-depth genetic analysis to identify genetic susceptibilities to guide personalized medicine approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Robert Polten,
  • Ivana Kutle,
  • Jan Lennart Stalp,
  • Jens Hachenberg,
  • Philipp John-Neek,
  • Ann-Kathrin Seyda,
  • Dhanya Ramachandran,
  • Rafaela Schmidtke,
  • Valeriia Obrizan,
  • Lara Kokemüller,
  • Doris Steinemann,
  • Jonathan Lühmann,
  • Yvonne Lisa Behrens,
  • Gudrun Göhring,
  • Stephan Bartels,
  • Malte Gronewold,
  • Lavinia Neubert,
  • Jan C. Kamp,
  • Dirk Schaudien,
  • Robert Geffers,
  • Peter Hillemanns,
  • Thilo Dörk,
  • Rüdiger Klapdor,
  • Michael Morgan,
  • Axel Schambach

摘要

Genetic profiling of a new HPV-negative cervical cancer model identified pathogenic variants in genes implicated in oncogenic signaling, cell cycle regulation, and DNA damage repair pathways, including homologous recombination, non-homologous end-joining, and mismatch repair. Deficiencies in BRCA2, RAD51 and MLH1 were among these actionable targets. The newly described cervical cancer model revealed sensitivity towards the PARP inhibitor olaparib, which was further augmented upon combination with platinum-based chemotherapeutics. In contrast, BRCA1/2-proficient cervical cancer cells exhibited greater resistance to these strategies. This study highlights the potential of in-depth genetic analysis to identify genetic susceptibilities to guide personalized medicine approaches.